Brought to you by 
Novo Nordisk, Innate target natural killer cells
28 Aug 2015
Executive Summary
Cancer immunotherapeutics company Innate Pharma and Novo Nordisk have extended their three-year-old collaboration--began in 2003--by another three years to research and develop drugs that target natural killer (NK) cells in the body. Under the new agreement, the companies have expanded the scope of therapeutic areas to include infectious diseases and autoimmune disorders in addition to the originally focused area of cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo Nordisk, Innate target natural killer cells
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice